Literature DB >> 14725615

Valproic acid is known to cause hypospadias in man but does not reduce anogenital distance or causes hypospadias in rats.

Bengt Källén1.   

Abstract

The use of valproic acid during human pregnancy increases the risk of hypospadias in the offspring. Rats exposed in utero to valproic acid did not develop hypospadias and even had a slightly increased anogenital distance in males 3-4 days after birth. A classical antiandrogenic drug, flutamide, caused hypospadias as well as a reduction of the anogenital distance in males. At the age of 3 months, rats exposed in utero with either valproic acid or flutamide showed a reduced testicular weight and hypoplasia of tubules, which seemed not to be related to the antiandrogenic activity of flutamide as it did not correlate with the presence of hypospadias. The mechanism through which valproic acid causes hypospadias in man and affects testicular development in rat is unknown. Hypospadias caused by valproic acid in man is apparently not due to anti-androgenic properties of the drug.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 14725615     DOI: 10.1111/j.1742-7843.2004.pto_940109.x

Source DB:  PubMed          Journal:  Basic Clin Pharmacol Toxicol        ISSN: 1742-7835            Impact factor:   4.080


  2 in total

1.  Risk of hypospadias in newborn infants exposed to valproic acid during the first trimester of pregnancy: a case-control study in Spain.

Authors:  Elvira Rodríguez-Pinilla; Consuelo Mejías; David Prieto-Merino; Paloma Fernández; María L Martínez-Frías
Journal:  Drug Saf       Date:  2008       Impact factor: 5.606

2.  Head-to-Head Study of Developmental Neurotoxicity and Resultant Phenotype in Rats: α-Hexabromocyclododecane versus Valproic Acid, a Recognized Model of Reference for Autism Spectrum Disorders.

Authors:  Chloé Morel; Armelle Christophe; Katy Maguin-Gaté; Justine Paoli; Jonathan David Turner; Henri Schroeder; Nathalie Grova
Journal:  Toxics       Date:  2022-04-06
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.